“…Previous experiences with major disruptions, such as armed conflicts or the Ebola outbreak in 2014, have demonstrated that important health gains could be lost in a short period of time ( Delamou et al, 2017 ; El Saghir, Soto Pérez de Celis, and Fares, 2018 ; Kieny, Evans, Schmets, and Kadandale, 2014 ). Both high-income countries (HICs) and low- and middle-income countries (LMICs) are susceptible to these disruptions and losses, and the negative effects of the COVID-19 pandemic on availability of resources for cancer control and research, as they are diverted to the emergency response, may exacerbate these common challenges ( DeBoer, Fadelu, Shulman, and Van Loon, 2020 ). For example, concerns have been expressed about the disruption of programs on HPV vaccination and cervical cancer screening, which have made great strides in the last decade ( Arbyn, Bruni, Kelly, et al, 2020 ; Rahman, Gultekin, and Lassi, 2020 ).…”